Overview

  • Product name

    Anti-GFAP antibody [GA-5] - BSA and Azide free
    See all GFAP primary antibodies
  • Description

    Mouse monoclonal [GA-5] to GFAP - BSA and Azide free
  • Host species

    Mouse
  • Specificity

    ab212398 shows no cross-reactivity with other intermediate filament proteins.
  • Tested applications

    Suitable for: Flow Cyt, IHC-P, WB, ICC/IFmore details
  • Species reactivity

    Reacts with: Mouse, Rat, Rabbit, Chicken, Cow, Human, Pig
  • Immunogen

    Full length native protein (purified) corresponding to Pig GFAP. GFAP isolated from Pig spinal cord
    Database link: F1RR02

  • Positive control

    • Human cerebellum whole cell lysate, Human cerebellum tissue, Brain or Astrocytoma.

Properties

Applications

Our Abpromise guarantee covers the use of ab212398 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
Flow Cyt Use 0.5-1µg for 106 cells.
IHC-P Use a concentration of 0.25 - 0.5 µg/ml. Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.
WB Use a concentration of 0.5 - 1 µg/ml. Predicted molecular weight: 49 kDa.
ICC/IF Use a concentration of 1 - 2 µg/ml.

Target

  • Function

    GFAP, a class-III intermediate filament, is a cell-specific marker that, during the development of the central nervous system, distinguishes astrocytes from other glial cells.
  • Tissue specificity

    Expressed in cells lacking fibronectin.
  • Involvement in disease

    Defects in GFAP are a cause of Alexander disease (ALEXD) [MIM:203450]. Alexander disease is a rare disorder of the central nervous system. It is a progressive leukoencephalopathy whose hallmark is the widespread accumulation of Rosenthal fibers which are cytoplasmic inclusions in astrocytes. The most common form affects infants and young children, and is characterized by progressive failure of central myelination, usually leading to death usually within the first decade. Infants with Alexander disease develop a leukoencephalopathy with macrocephaly, seizures, and psychomotor retardation. Patients with juvenile or adult forms typically experience ataxia, bulbar signs and spasticity, and a more slowly progressive course.
  • Sequence similarities

    Belongs to the intermediate filament family.
  • Post-translational
    modifications

    Phosphorylated by PKN1.
  • Cellular localization

    Cytoplasm. Associated with intermediate filaments.
  • Information by UniProt
  • Database links

  • Alternative names

    • wu:fb34h11 antibody
    • ALXDRD antibody
    • cb345 antibody
    • etID36982.3 antibody
    • FLJ42474 antibody
    • FLJ45472 antibody
    • GFAP antibody
    • GFAP_HUMAN antibody
    • gfapl antibody
    • Glial fibrillary acidic protein antibody
    • Intermediate filament protein antibody
    • wu:fk42c12 antibody
    • xx:af506734 antibody
    • zgc:110485 antibody
    see all

Images

  • Immunohistochemistry of Formalin/PFA-fixed paraffin-embedded Human cerebellum tisue labeling GFAP with ab212398 at 0.5μg/ml.

  • Anti-GFAP antibody [GA-5] - BSA and Azide free (ab212398) at 1 µg/ml + Human cerebellum lysate

    Predicted band size: 49 kDa

References

This product has been referenced in:

  • Li Y  et al. A novel model of persistent retinal neovascularization for the development of sustained anti-VEGF therapies. Exp Eye Res 174:98-106 (2018). IHC-P . Read more (PubMed: 29852133) »
See 1 Publication for this product

Customer reviews and Q&As

There are currently no Customer reviews or Questions for ab212398.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
For licensing inquiries, please contact partnerships@abcam.com

Sign up